Botulinum toxin type A (BTX-A) represents the gold standard therapy for focal spasticity after stroke, with low prevalence of complications, reversibility, and efficacy in reducing spastic hypertonia. Current guidelines suggest the employment of a dosage up to 600 units (U) of BTX-A to treat spasticity after stroke, to avoid important adverse effects and the development of antibodies against the neurotoxin. In recent years, NT 201, a new BTX-A free of complexing proteins, has been used for treating several movement disorders, showing safety and efficacy in upper limb spasticity. In a prospective, non-randomized, open-label study, we studied the efficacy and safety of higher doses of BTX-A NT 201 (up to 840 U) in 25 consecutive patients with upper and lower limb spasticity after stroke, evaluated at 30 and 90 days after injections. Before and after the treatment, the grade of spasticity, the disability, and spasticity-related pain were extensively measured. After 30 days of follow-up, a great reduction of spasticity and pain with improvement of disability was observed. The effects were still present at 90 days of follow-up. No major adverse events were observed. Higher doses of BTX-A NT 201 appeared to be safe and efficacious in patients with upper and lower limb spasticity after stroke. However, further investigations are needed to determine its reproducibility in larger case series or randomized clinical trials and to observe the absence of antibodies against the neurotoxin also after repeated injections.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00702-012-0892-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: Current care plans for stroke survivors typically focus on acute management, resulting in many stroke survivors being discharged to their communities without adequate follow-up, despite their often experiencing significant post-stroke complications, such as post-stroke spasticity (PSS). While studies have explored the incidence and prevalence of PSS, little is known about how early PSS develops and how many stroke survivors develop 'problematic' PSS that would benefit from pharmacological treatment.
Methods And Analysis: EPITOME is a prospective, international, observational, epidemiological study of participants (aged 18-90 years) who develop paresis within days 3-14 of a first-ever stroke that occurred within the past 4 weeks.
Design, modeling, and preliminary evaluation of a simple wrist-hand stretching orthosis for neurologically impaired patients.
Wearable Technol
December 2024
Department of Mechanical Engineering, Vanderbilt University, Nashville, TN, USA.
This work studies upper-limb impairment resulting from stroke or traumatic brain injury and presents a simple technological solution for a subset of patients: a soft, active stretching aid for at-home use. To better understand the issues associated with existing associated rehabilitation devices, customer discovery conversations were conducted with 153 people in the healthcare ecosystem (60 patients, 30 caregivers, and 63 medical providers). These patients fell into two populations: spastic (stiff, clenched hands) and flaccid (limp hands).
View Article and Find Full Text PDFTranscutaneous electrical acupoint stimulation for upper limb spasticity after stroke: effect andd feasibility-a randomised pilot study.
BMJ Support Palliat Care
January 2025
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, Tianjin, China
Importance: Limb spasticity is a common issue among stroke patients. Transcutaneous electrical acupoint stimulation (TEAS) is recommended as an alternative therapy for managing upper limb spasticity after stroke; however, its potential effects and feasibility remain uncertain.
Objective: To investigate the potential effects and feasibility of TEAS on motor function in patients with upper limb spasticity after stroke.
Bioinspired Smart Triboelectric Soft Pneumatic Actuator-Enabled Hand Rehabilitation Robot.
Adv Mater
January 2025
Division of Intelligent and Biomechanical Systems, State Key Laboratory of Tribology in Advanced Equipment, Department of Mechanical Engineering, Tsinghua University, Haidian, Beijing, 100084, China.
Quantitative assessment for post-stroke spasticity remains a significant challenge due to the encountered variable resistance during passive stretching, which can lead to the widely used modified Ashworth scale (MAS) for spasticity assessment depending heavily on rehabilitation physicians. To address these challenges, a high-force-output triboelectric soft pneumatic actuator (TENG-SPA) inspired by a lobster tail is developed. The bioinspired TENG-SPA can generate approximately 20 N at 0.
View Article and Find Full Text PDFEffects of Intensive Impairment-Oriented Arm Rehabilitation for Chronic Stroke Survivors: An Observational Cohort Study.
J Clin Med
December 2024
Hand and Occupational Therapy Outpatient Service Laborn, 80802 München, Germany.
: To assess the effects of a two-week course of intensive impairment-oriented arm rehabilitation for chronic stroke survivors on motor function. : An observational cohort study that enrolled chronic stroke survivors (≥6 months after stroke) with mild to severe arm paresis, who received a two-week course of impairment-oriented and technology-supported arm rehabilitation (1:1 participant-therapist setting), which was carried out daily (five days a week) for four hours. The outcome measures were as follows: the primary outcome was the arm motor function of the affected arm (mild paresis: BBT, NHPT; severe paresis: Fugl-Meyer arm motor score).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!